ES2194017T3 - Proceso para producir polipeptidos, proteinas o peptidos hidrofobos. - Google Patents

Proceso para producir polipeptidos, proteinas o peptidos hidrofobos.

Info

Publication number
ES2194017T3
ES2194017T3 ES94109676T ES94109676T ES2194017T3 ES 2194017 T3 ES2194017 T3 ES 2194017T3 ES 94109676 T ES94109676 T ES 94109676T ES 94109676 T ES94109676 T ES 94109676T ES 2194017 T3 ES2194017 T3 ES 2194017T3
Authority
ES
Spain
Prior art keywords
proteins
peptides
polypeptides
hydrophobe
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94109676T
Other languages
English (en)
Inventor
Heinz Dobeli
Nicholas Draeger
Trottman Gerda Huber
Peter Jakob
Dietrich Stuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2194017T3 publication Critical patent/ES2194017T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PROPORCIONA METODOS ADECUADOS PARA LA PRODUCCION Y PURIFICACION DE POLIPEPTIDOS HIROFOBICOS, PROTEINAS O PEPTIDOS. LA INVENCION ADEMAS PROPORCIONA PROTEINAS DE FUSION UTILES PARA LA PRODUCCION Y PURIFICACION DE LOS MENCIONADOS POLIPEPTIDOS HIDROFOBICOS, PROTEINAS O PEPTIDOS. ADEMAS, LA INVENCION PROPORCIONA EL PEPTIDO B AMILOIDE MONOMERICO HOMOGENEO Y PRUEBAS PARA VISUALIZAR MEDICAMENTOS AMILOIDES INHIBIDORES DE LA TOXICIDAD QUE USAN EL MENCIONADO PEPTIDO B ERICO.
ES94109676T 1993-07-06 1994-06-23 Proceso para producir polipeptidos, proteinas o peptidos hidrofobos. Expired - Lifetime ES2194017T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93110755 1993-07-06

Publications (1)

Publication Number Publication Date
ES2194017T3 true ES2194017T3 (es) 2003-11-16

Family

ID=8213046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94109676T Expired - Lifetime ES2194017T3 (es) 1993-07-06 1994-06-23 Proceso para producir polipeptidos, proteinas o peptidos hidrofobos.

Country Status (14)

Country Link
US (1) US5750374A (es)
EP (2) EP1304381A3 (es)
JP (2) JP2947401B2 (es)
CN (3) CN1916017A (es)
AT (1) ATE236984T1 (es)
AU (1) AU666274B2 (es)
CA (1) CA2125467C (es)
DE (1) DE69432449T2 (es)
DK (1) DK0641861T3 (es)
ES (1) ES2194017T3 (es)
NZ (1) NZ260907A (es)
PT (1) PT641861E (es)
RU (1) RU94023251A (es)
ZA (1) ZA944686B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
GB9618952D0 (en) 1996-09-11 1996-10-23 Sandoz Ltd Process
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
NZ514414A (en) 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1187920A2 (en) * 1999-06-09 2002-03-20 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
EP1226241A1 (en) * 1999-10-21 2002-07-31 Panorama Research, Inc. A general method for optimizing the expression of heterologous proteins
US7799561B2 (en) * 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
FR2859221B1 (fr) * 2003-08-28 2005-10-14 Centre Nat Rech Scient Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
US7741053B2 (en) * 2005-05-13 2010-06-22 Sigma-Aldrich Co. Processes for purification of recombinant proteins
KR100621354B1 (ko) * 2005-06-14 2006-09-08 광주과학기술원 유비퀴틴을 이용한 아밀로이드-베타 펩티드의 제조방법
WO2010063460A1 (en) * 2008-12-02 2010-06-10 Universität Zürich Recombinant production of hydrophobic peptides and fusion proteins for use in producing same
US20170226159A1 (en) * 2014-09-26 2017-08-10 Kaneka Corporation Method for producing hydrophobic peptide
US10118956B2 (en) 2014-12-01 2018-11-06 Pfenex Inc. Fusion partners for peptide production
CN105001307B (zh) 2015-07-31 2016-08-24 南京斯拜科生化实业有限公司 一种溶解难溶多肽的偶联肽链及其在液相色谱中分离纯化的应用
CN119930779A (zh) * 2025-02-10 2025-05-06 南京工业大学 采用淀粉样蛋白基序调节嵌合蛛丝蛋白亲疏水性的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207044A1 (en) * 1985-06-20 1986-12-30 Monsanto Company Release of peptides from polypeptides
AU6104586A (en) * 1985-08-12 1987-02-19 Malcolm A. Martin Aids protein using trple gene
AU7234387A (en) * 1986-03-24 1987-10-20 Ortho Pharmaceutical Corporation Synthetic htlv-iii peptides, compositions and uses thereof
US5047513A (en) * 1986-07-10 1991-09-10 Hoffmann-La Roche Inc. Metal chelate resins
CA1304886C (en) * 1986-07-10 1992-07-07 Heinz Dobeli Metal chelate resins
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5416007A (en) * 1987-03-20 1995-05-16 Creative Biomolecules, Inc. Enhanced proteolytic cleavage of recombinant fusion proteins
US5124255A (en) * 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
IT1226728B (it) * 1988-08-05 1991-02-05 Eniricerche Spa Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
US5045190A (en) * 1988-11-08 1991-09-03 Carbonell Ruben G Chromatography apparatus
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
EP0546101A1 (en) * 1990-08-24 1993-06-16 The President And Fellows Of Harvard College METHOD OF INTERFERING WITH FORMATION OF $g(a)-ANTICHYMOTRYPSIN-$g(b)-PROTEIN COMPLEX AND SYNTHETIC PEPTIDES FOR USE THEREIN
DK0484787T3 (da) * 1990-11-03 2002-02-04 Dade Behring Marburg Gmbh HCV-specifikke peptider, fremgangsmåde til opnåelse deraf og anvendelse deraf
NZ243636A (en) * 1991-07-29 1993-06-25 Iaf Biochem Int Immunoassay and kit for simultaneously detecting antibodies to hiv-1, hiv-2, htlv-1 and htlv-11
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease

Also Published As

Publication number Publication date
DE69432449D1 (de) 2003-05-15
AU666274B2 (en) 1996-02-01
JPH07102000A (ja) 1995-04-18
JPH1143500A (ja) 1999-02-16
CN1916017A (zh) 2007-02-21
CA2125467C (en) 2001-02-06
EP1304381A3 (en) 2003-05-02
NZ260907A (en) 1996-06-25
RU94023251A (ru) 1996-05-10
CN1057535C (zh) 2000-10-18
CN1227846A (zh) 1999-09-08
DK0641861T3 (da) 2003-07-28
EP0641861B1 (en) 2003-04-09
EP1304381A2 (en) 2003-04-23
CA2125467A1 (en) 1995-01-07
JP2947401B2 (ja) 1999-09-13
US5750374A (en) 1998-05-12
ATE236984T1 (de) 2003-04-15
DE69432449T2 (de) 2004-04-08
EP0641861A2 (en) 1995-03-08
AU6612294A (en) 1995-01-27
ZA944686B (en) 1995-01-06
CN100439391C (zh) 2008-12-03
CN1098416A (zh) 1995-02-08
PT641861E (pt) 2003-07-31
EP0641861A3 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
ES2194017T3 (es) Proceso para producir polipeptidos, proteinas o peptidos hidrofobos.
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE69434520D1 (de) Biotinylierung von proteinen
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
DE69122494D1 (de) Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
ES2076521T3 (es) Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga.
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
ES2110996T3 (es) Alergeno de polen de ballico.
DE69010155D1 (de) Verfahren zur Trennung von Aminosäuren.
ES2094725T3 (es) Peptidos hcg para la aplicacion en procedimientos de purificacion de anticuerpos.
EP1117682A4 (en) Novel peptides
FI904087A7 (fi) Monoklonaalisia vasta-aineita aktivoituja ras-proteiineja vastaan, joi lla on aminohappomutaatioita proteiinin kohdassa 13
ATE189232T1 (de) Protein-s polypeptide und deren verwendungen
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
BR1100801A (pt) Proteìna, peptìdeo, proteìna ou peptìdeo, sequência de dna, processo para a preparação de uma proteìna ou peptìdeo, anticorpo, composição farmacêutica, e, uso de uma proteìna ou peptìdeo
BR1100350A (pt) Peptìdeo-sinal, sequências de adn codificando para este, vetores de expressão portando uma dessas sequências e processo de produção periplásmica de um polipetìdeo